Bladder Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Bladder Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 6 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNCT02138734Complete Response (CR) Rate | Phase 1/2 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-03-31 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235Recurrence Free Survival (RFS) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-01 |
| TYRA | Tyra Biosciences, Inc | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD). | Phase 1/2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-01-12 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationNCT07038928observationalProportion of patients receiving any intravesical treatment among patients with high-risk NMIBC | — | Recruiting | 2026-12-31 | in 133 d | 2026-08-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Bladder Cancer
most recently updated first123 studies match. Showing the first 100 of 123 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerNCT07206225Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants only | Phase 1 | Recruiting | Drug: PF-08052667, Sasanlimab, BCG, PF-02921367 | Non-muscle Invasive Bladder Cancer | 294 | 2025-11-06 | 2030-01-29 | in 1,258 d | 2026-08-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractNCT07218380Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab | Phase 3 | Recruiting | Drug: Vepugratinib, EV, Pembrolizumab · Other: Placebo | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis | 450 | 2025-12-12 | Oct 2029 | ≤ 1,168 d | 2026-08-17 |
| PHO.OL | Photocure | — | Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyNCT07144319observationalVideo and image collection | — | Recruiting | — | Bladder Cancer, Non-muscle Invasive Bladder Cancer | 500 | 2026-03-25 | Dec 2027 | ≤ 498 d | 2026-08-14 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)NCT07763197observationalNumber of Completed Participants with Blood, Urine and Residual Tissue Specimens Collected | — | Recruiting | — | Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer | 400 | 2026-07-27 | Jul 2032 | ≤ 2,172 d | 2026-08-13 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| AZN | AstraZeneca | — | TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationNCT07038928observationalProportion of patients receiving any intravesical treatment among patients with high-risk NMIBC | — | Recruiting | — | Bladder Cancer | 600 | 2025-06-30 | 2026-12-31 | in 133 d | 2026-08-10 |
| AURA | Aura Biosciences | $846M | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerNCT05483868Safety of AU-011: Incidences of SAEs and DLTs | Phase 1 | Active, not recruiting | Drug: AU-011 · Combination product: AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration | Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder | 55 | 2022-09-26 | Mar 2027 | ≤ 223 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)NCT03459846results2022-10-26Progression-free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: Durvalumab, Olaparib, Placebo | Urinary Bladder Neoplasms | 154 | 2018-03-16 | 2020-10-15actual | — | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| AZN | AstraZeneca | — | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)NCT06960577The safety of neoadjuvant durvalumab combined with ddMVAC or gem/cis prior to radical cystectomy (RC). | Phase 3 | Recruiting | Drug: Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine | 150 | 2025-05-15 | 2028-10-31 | in 803 d | 2026-08-04 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaNCT07129993Overall Response Rate - Part A (Phase 2) | Phase 2/3 | Recruiting | Drug: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine | Urothelial Cancer, Bladder Cancer | 630 | 2025-09-26 | 2029-06-01 | in 1,016 d | 2026-07-27 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| AZN | AstraZeneca | — | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCNCT03732677results2025-07-03Pathologic Complete Response (pCR) Rates at Time of Cystectomy | Phase 3 | Active, not recruiting | Drug: Durvalumab, Cisplatin, Gemcitabine | Muscle Invasive Bladder Cancer | 1,063 | 2018-11-16 | 2024-04-29actual | — | 2026-07-17 |
| CGON | CG Oncology, Inc. | $6.8B | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591Cohort C: | Phase 3 | Active, not recruiting | Biological: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 190 | 2020-10-27 | 2030-06-16 | in 1,396 d | 2026-07-10 |
| AZN | AstraZeneca | — | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerNCT03528694The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC | Phase 3 | Active, not recruiting | Biological: Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG) | Non-muscle-invasive Bladder Cancer | 1,018 | 2018-05-14 | 2025-04-03actual | — | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| CGON | CG Oncology, Inc. | $6.8B | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235Recurrence Free Survival (RFS) | Phase 3 | Active, not recruiting | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 367 | 2023-12-14 | Nov 2026 | ≤ 102 d | 2026-07-01 |
| TARA | Protara Therapeutics | — | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerNCT05951179Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 | Phase 2 | Recruiting | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 131 | 2023-09-15 | Oct 2031 | ≤ 1,898 d | 2026-06-30 |
| LLY | Eli Lilly and Company | $1.15T | Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsNCT07675057expanded access | — | Available | Drug: Vepugratinib | Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell | — | — | — | — | 2026-06-30 |
| TARA | Protara Therapeutics | — | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerNCT07480356Incidence of high-grade complete response | Phase 3 | Recruiting | Drug: TARA-002, Investigator's Choice of Intravesical Chemotherapy | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 284 | 2026-05-29 | Apr 2028 | ≤ 619 d | 2026-06-29 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3NCT05614739Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: LOXO-435, Pembrolizumab, enfortumab vedotin | Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms | 535 | 2023-01-12 | Jun 2027 | ≤ 314 d | 2026-06-18 |
| AZN | AstraZeneca | — | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinNCT04960709To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part) | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab, Enfortumab Vedotin · Procedure: Radical Cystectomy | Muscle Invasive Bladder Cancer | 712 | 2021-08-05 | 2026-03-02actual | — | 2026-06-04 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| IBRX | ImmunityBio, Inc. | $8.2B | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerNCT07551544Clinical Complete Response (CR) Rate | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) | NMIBC | 0 | 2026-05-15 | May 2032 | ≤ 2,111 d | 2026-05-19 |
| IBRX | ImmunityBio, Inc. | $8.2B | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerNCT06810141expanded access | — | Available | Biological: rMBCG | NMIBC | — | — | — | — | 2026-05-14 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT05243550results2024-11-04Complete Response Rate (CRR) | Phase 3 | Active, not recruiting | Drug: UGN-102 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 240 | 2022-03-01 | 2023-04-26actual | — | 2026-05-11 |
| IBRX | ImmunityBio, Inc. | $8.2B | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05981131observationalObtain Long Term Follow-Up data to be summarized using descriptive statistics | — | Active, not recruiting | Drug: N803 plus Bacillus Calmette-Guerin (BCG) | Non Muscle Invasive Bladder Cancer | 6 | 2023-08-17 | 2033-08-30 | in 2,567 d | 2026-04-29 |
| AZN | AstraZeneca | — | Cancer in Patients on Dapagliflozin and Other Antidiabetic TreatmentNCT02695121observationalIncidence of breast cancer | — | Completed | — | Breast Cancer, Bladder Cancer | 2,133,575 | 2017-01-01 | 2025-01-30actual | — | 2026-04-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerNCT03661320Pathological Complete Response (pCR) rate, in all randomized participants | Phase 3 | Active, not recruiting | Biological: Nivolumab · Drug: Gemcitabine, Cisplatin | Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer | 855 | 2018-11-06 | 2026-02-16actual | — | 2026-04-15 |
| CGON | CG Oncology, Inc. | $6.8B | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGNCT06443944expanded access | — | Available | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer | — | — | — | — | 2026-04-14 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| CGON | CG Oncology, Inc. | $6.8B | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerNCT02143804Durable Complete Response Proportion | Phase 2 | Withdrawnsponsor's stated reason: Change in trial design | Biological: oncolytic adenovirus expressing GMCSF | Bladder Cancer, High Grade, Non Muscle Invasive | 0 | Mar 2014 | Mar 2015actual | — | 2026-04-02 |
| IBRX | ImmunityBio, Inc. | $8.2B | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNCT02138734Complete Response (CR) Rate | Phase 1/2 | Active, not recruiting | Biological: BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation) | Non-muscle Invasive Bladder Cancer | 369 | 2014-07-21 | 2026-09-30 | in 41 d | 2026-03-31 |
| IBRX | ImmunityBio, Inc. | $8.2B | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGNCT06800963The primary endpoint is to assess safety as measured by the incidence and severity of adverse events. | Phase 1/2 | Recruiting | Biological: Intravesical Recombinant Mycobacterium (rMBCG) | NMIBC | 40 | 2025-10-15 | Feb 2028 | ≤ 558 d | 2026-03-27 |
| PFE | Pfizer | $155.3B | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerNCT06580938Number of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Biological: PF-07921585, Sasanlimab | Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer | 4 | 2024-11-11 | 2025-07-14actual | — | 2026-03-23 |
| PFE | Pfizer | $155.3B | A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerNCT04165317results2026-01-22Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C | Phase 3 | Active, not recruiting | Drug: PF-06801591, Bacillus Calmette-Guerin | Non-muscle Invasive Bladder Cancer | 1,068 | 2019-12-30 | 2024-12-02actual | — | 2026-01-22 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299Complete response rate (CRR) | Phase 3 | Active, not recruiting | Drug: UGN-103 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 99 | 2024-08-29 | 2025-09-11actual | — | 2026-01-15 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)NCT05375903Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: UGN-301, UGN-201, Gemcitabine | Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent | 51 | 2022-06-01 | 2026-01-09actual | — | 2026-01-14 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD). | Phase 1/2 | Active, not recruiting | Drug: TYRA-300 | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma | 310 | 2022-11-22 | Nov 2026 | ≤ 102 d | 2026-01-12 |
| AZN | AstraZeneca | — | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerNCT02546661Module A: The frequency and nature of adverse events related to AZD4547 monotherapy. | Phase 1 | Active, not recruiting | Drug: AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib | Muscle Invasive Bladder Cancer | 117 | 2016-12-28 | 2020-03-18actual | — | 2025-12-29 |
| PHO.OL | Photocure | — | Blue Light Cystoscopy With Cysview® RegistryNCT02660645observationalRate of detection of bladder malignancies | — | Recruiting | Drug: Hexaminolevulinate hydrochloride (HCL) · Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Bladder Cancer | 4,400 | Apr 2014 | Dec 2028 | ≤ 864 d | 2025-12-18 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825Complete Response | Phase 2/3 | Active, not recruiting | Drug: N-803 and BCG, N-803 | Bladder Cancer | 190 | 2017-06-02 | 2024-10-01actual | — | 2025-10-16 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)NCT04149574results2025-09-16Part 2: Event Free Survival | Phase 3 | Terminatedsponsor's stated reason: Insufficient enrollment, inability to meet protocol objectives, and slow accrual. | Drug: nivolumab · Other: Placebo · Biological: Bacillus Calmette-Guérin (BCG) | Urinary Bladder Neoplasms | 13 | 2020-01-15 | 2023-10-31actual | — | 2025-09-16 |
| INCY | Incyte Corporation | $24.7B | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2016-09-14 | 2020-04-30actual | — | 2025-08-05 |
| ALXO | ALX Oncology Inc. | $288M | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)NCT05524545First Cycle Dose limiting toxicities (DLTs) | Phase 1 | Completed | Drug: Evorpacept, Enfortumab Vedotin | Bladder Cancer, Urothelial Carcinoma | 36 | 2022-11-02 | 2025-06-27actual | — | 2025-07-25 |
| INCY | Incyte Corporation | $24.7B | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE) | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2021-02-03 | 2024-01-22actual | — | 2025-07-11 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| RLMD | Relmada Therapeutics, Inc. | $517M | Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBCNCT06663137Number of Patients with Complete Response (CR) in High-Grade NMIBC | Phase 2 | Recruiting | Drug: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Non Muscle Invasive Bladder Cancer | 70 | 2024-08-01 | Aug 2025 | — | 2025-06-13 |
| MNPR | Monopar Therapeutics | $799M | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsNCT06337084To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr | Phase 1 | Recruiting | Drug: MNPR-101-DFO*-89Zr · Diagnostic test: PET/CT Diagnostic Imaging | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-05-30 | Apr 2026 | — | 2025-05-22 |
| MNPR | Monopar Therapeutics | $799M | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Drug: MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-10-08 | Dec 2026 | ≤ 133 d | 2025-05-21 |
| APRE | Aprea Therapeutics | $8M | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesNCT04383938results2025-05-13To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. | Phase 1/2 | Completed | Drug: APR-246 (eprenetapopt) + Pembrolizumab | Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor | 40 | 2020-06-25 | 2022-04-30actual | — | 2025-05-13 |
| TEM | Tempus AI | $8.6B | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | Other: Observation | Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer | 1,000 | 2020-10-19 | 2026-10-19 | in 60 d | 2025-05-06 |
| AZN | AstraZeneca | — | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERNCT05945108observationalClinical staging | — | Completed | — | Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Muscle-invasive Bladder Cancer | 400 | 2023-07-10 | 2024-04-18actual | — | 2025-04-11 |
| TARA | Protara Therapeutics | — | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)NCT05085977Phase 1a, Dose Escalation Phase: Incidence of DLT AEs in subjects with HGTa or CIS NMIBC | Phase 1 | Completed | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 12 | 2022-03-10 | 2024-09-03actual | — | 2025-01-27 |
| TARA | Protara Therapeutics | — | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)NCT05085990Phase 1b, Dose Expansion Phase: Incidence of AEs in subjects with CIS NMIBC with active disease | Phase 1 | Completed | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 10 | 2023-05-08 | 2024-09-12actual | — | 2025-01-27 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the BladderNCT05742867observationalOverall survival | — | Completed | — | Urinary Bladder Neoplasms | 115 | 2023-05-31 | 2024-07-10actual | — | 2025-01-23 |
| PHO.OL | Photocure | — | Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder CancerNCT05600322results2024-10-03Number of Patients With Histology-confirmed Lesions (Ta, T1, or CIS) Who Have at Least One Such Lesion Found by Hexvix Blue Light Cystoscopy But Not by White Light Cystoscopy. | Phase 3 | Completed | Drug: Hexaminolevulinate Hydrochloride · Device: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system | Bladder Cancer | 158 | 2022-11-03 | 2023-07-12actual | — | 2024-10-03 |
| AZN | AstraZeneca | — | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursNCT05397171results2024-10-01Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated. | Drug: AZD8853, Zirconium-89 crefmirlimab berdoxam | Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung | 17 | 2022-06-07 | 2023-06-06actual | — | 2024-10-01 |
| CGON | CG Oncology, Inc. | $6.8B | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461Complete response rate in patients | Phase 2 | Completed | Biological: CG0070, Pembrolizumab Injection · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer | 35 | 2020-12-08 | 2023-03-07actual | — | 2024-09-25 |
| URGN | UroGen Pharma Ltd. | $2.4B | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05136898results2024-09-19Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest. | Phase 3 | Completed | Drug: UGN-102 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 8 | 2021-11-30 | 2023-02-02actual | — | 2024-09-19 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerNCT03219333results2021-12-17Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | Phase 2 | Completed | Drug: Enfortumab vedotin | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms | 219 | 2017-10-08 | 2020-10-27actual | — | 2024-08-27 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerNCT04209114results2024-06-27Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care | Phase 3 | Completed | Biological: Nivolumab, Bempegaldesleukin · Procedure: Radical cystectomy (RC) | Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer | 114 | 2020-02-05 | 2023-06-07actual | — | 2024-06-27 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2018-11-09 | 2022-12-14actual | — | 2024-06-13 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931results2024-06-06Disease-free Survival (DFS) | Phase 3 | Terminatedsponsor's stated reason: Alternate approach pursued | Drug: UGN-102 · Procedure: TURBT | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 282 | 2021-02-19 | 2023-03-17actual | — | 2024-06-06 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2018-07-24 | 2021-08-18actual | — | 2024-05-24 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder CancerNCT05699135observationalOverall survival | — | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns. | Drug: Avelumab first-line maintenance | Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma | 150 | 2023-03-09 | 2023-06-30actual | — | 2024-04-24 |
| PFE | Pfizer | $155.3B | Study of PF-07263689 in Participants With Selected Advanced Solid TumorsNCT05061537results2024-04-12Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study. | Biological: PF-07263689, Sasanlimab | Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma | 13 | 2021-10-20 | 2022-10-14actual | — | 2024-04-12 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| PCSA | Processa Pharmaceuticals | $6M | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced MalignanciesNCT02030067results2023-12-06Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 | Phase 1/2 | Completed | Drug: RX-3117 | Solid Tumor, Metastatic Bladder Cancer | 127 | Dec 2013 | Jul 2019actual | — | 2023-12-06 |
| PFE | Pfizer | $155.3B | A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial CancerNCT05568407observationalOverall Survival (OS) | — | Terminatedsponsor's stated reason: The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns. | Drug: Avelumab | Bladder Cancer | 19 | 2023-01-18 | 2023-06-16actual | — | 2023-07-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderNCT03519256results2023-06-01Number of Participants With Adverse Events (AEs) | Phase 2 | Terminatedsponsor's stated reason: Insufficient Enrollment | Biological: Nivolumab, BCG · Drug: BMS-986205 | Urinary Bladder Neoplasms | 142 | 2018-08-02 | 2022-08-22actual | — | 2023-06-01 |
| NKTR | Nektar Therapeutics | $2.5B | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerNCT03785925results2023-03-28Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) Expression | Phase 2 | Completed | Biological: Bempegaldesleukin, Nivolumab | Urinary Bladder Neoplasm, Neoplasm Metastasis | 192 | 2019-04-29 | 2022-02-09actual | — | 2023-03-28 |
| PFE | Pfizer | $155.3B | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)NCT05259397Number of participants with Dose limiting toxicities | Phase 1 | Withdrawnsponsor's stated reason: Pfizer has decided to terminate Study C4661001 due to strategic considerations. This decision is not due to any specific safety reasons or requests from any regulatory authorities. No participants have been enrolled in this study. | Drug: PF-07225570, sasanlimab | Bladder Cancer | 0 | 2022-03-24 | 2022-09-19actual | — | 2023-03-08 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerNCT03558503results2022-07-25Complete Response (CR) Rate for UGN-102 Treatment | Phase 2 | Completed | Drug: UGN-102 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 63 | 2018-10-15 | 2020-01-03actual | — | 2022-09-16 |
| 4523.T | Eisai Inc. | $8.7B | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder CancerNCT01126749results2022-02-28Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated as per sponsor's decision | Drug: Gemcitabine, E7389, Cisplatin | Bladder Cancer | 92 | 2010-04-16 | 2015-05-08actual | — | 2022-02-28 |
| INCY | Incyte Corporation | $24.7B | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersNCT02178722results2019-12-19Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events | Phase 1/2 | Completed | Drug: MK-3475, INCB024360 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC) | 444 | 2014-07-17 | 2018-11-26actual | — | 2022-02-14 |
| MGNX | MacroGenics | $261M | Safety Study of MGA271 in Refractory CancerNCT01391143Safety | Phase 1 | Completed | Biological: MGA271 | Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer | 179 | Jul 2011 | 2019-04-18actual | — | 2022-02-08 |
| MGNX | MacroGenics | $261M | Safety Study of MGD009 in B7-H3-expressing TumorsNCT02628535Number of participants with adverse events | Phase 1 | Terminatedsponsor's stated reason: Business decision (not for safety reasons) | Biological: MGD009 | Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma | 67 | Sep 2015 | 2019-11-25actual | — | 2022-02-08 |
| 4507.T | Shionogi | $15.7B | First-in-human Study of S-588210 (S-488210+S-488211)NCT04316689Number of Participants with Adverse Events | Phase 1 | Completed | Biological: S-488210, S-488211 | Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer, Mesothelioma | 10 | 2019-07-30 | 2021-09-22actual | — | 2022-01-26 |
| HALO | Halozyme Therapeutics | $11.9B | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerNCT00318643results2021-10-29Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC | Phase 1/2 | Completed | Drug: Mitomycin C, Chemophase | Bladder Cancer | 27 | 2006-03-30 | 2009-08-11actual | — | 2021-10-29 |
| AMBU-B.CO | Ambu A/S | — | Single-use Cystoscope System for Direct Visualization of the Urethra and BladderNCT04190641performance of Ambu® aScope™ 4 Cysto and aView™ Urologia | Not applicable | Completed | Device: Ambu aScope 4 Cysto and aView Urologia | Cystoscope, Bladder Cancer, Lower Urinary Tract Symptoms | 4 | 2020-10-08 | 2021-04-30actual | — | 2021-10-14 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| CGON | CG Oncology, Inc. | $6.8B | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerNCT01438112Complete Response Proportion (CR) | Phase 2/3 | Terminatedsponsor's stated reason: Change in study design | Biological: CG0070 Adenovirus Vector · Other: Control Arm: Quadruple Choice | Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors | 22 | Mar 2014 | Jun 2016actual | — | 2021-04-14 |
| CGON | CG Oncology, Inc. | $6.8B | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailureNCT02365818Durable Complete Response Proportion (DCR) | Phase 2 | Completed | Biological: CG0070 | Bladder Cancer | 66 | 2015-06-02 | Aug 2018actual | — | 2021-04-14 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) ExpressionNCT03125200results2019-08-28Number of Participants Who Experienced Dose-Limiting Toxicities | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: ADCT-502 | Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer | 21 | 2017-05-18 | 2018-04-05actual | — | 2021-02-01 |
| 4523.T | Eisai Inc. | $8.7B | A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102NCT04109092Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Withdrawnsponsor's stated reason: There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020. | Drug: E7766 | Urinary Bladder Neoplasms | 0 | 2020-02-13 | 2022-09-29 | — | 2020-12-14 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)NCT010944962 year Recurrence-Free Survival Rate | Phase 2 | Terminatedsponsor's stated reason: Portfolio prioritization due to slow enrollment | Biological: CDX-1307 Vaccine Regimen · Drug: Chemotherapy | Bladder Cancer | 3 | Apr 2010 | Jul 2011actual | — | 2020-02-13 |
| PHO.OL | Photocure | — | Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURBNCT01166230results2013-11-14observationalRecurrence Free Survival | — | Completed | — | Bladder Cancer | 551 | Jun 2010 | Dec 2010actual | — | 2019-04-09 |
| PHO.OL | Photocure | — | A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingNCT02560584results2018-07-02Proportion of Patients With Histologically Confirmed Malignancy Where Malignancy is Only Detected With Blue Light Cystoscopy With Cysview and Not White Light Cystoscopy | Phase 3 | Completed | Drug: Hexaminolevulinate hydrochloride · Device: KARL STORZ D-Light C PDD Flexible Videoscope System | Bladder Cancer | 304 | 2015-10-01 | 2017-04-05actual | — | 2018-07-02 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerNCT02543645Phase l: Safety and tolerability of varlilumab in combination with atezolizumab as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities and laboratory test abnormalities. | Phase 1 | Terminatedsponsor's stated reason: Portfolio re-prioritization | Drug: Combination of Varlilumab and Atezolizumab | Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer | 18 | Oct 2015 | Apr 2017actual | — | 2018-04-30 |
| URGN | UroGen Pharma Ltd. | $2.4B | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC PatientsNCT02307487Rate of Adverse Events (AE) findings considered to be dose limiting according to the CTCAE V 4.0 | Phase 2 | Completed | Drug: 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel, 120 mg MMC in 60ml gel, 140 mg MMC in 60ml gel, 160 mg MMC in 60ml gel | Bladder Cancer, Neoplasms, Urinary Bladder Diseases, Urologic Diseases | 14 | Dec 2014 | Apr 2016actual | — | 2017-06-16 |
| AMGN | Amgen | $229.9B | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456results2014-08-15observationalPercentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL | — | Completed | — | Anemia, Breast Cancer, Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumors, Bladder Cancer, Endometrial Cancer, Renal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer | 1,262 | Oct 2011 | Aug 2013actual | — | 2017-03-20 |
| ACHV | Achieve Life Sciences | $774M | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerNCT01454089Overall Survival (OS) | Phase 2 | Completed | Drug: OGX-427 600 mg, OGX-427 1000 mg, Placebo, Gemcitabine, Cisplatin, Carboplatin | Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms | 183 | Oct 2011 | Nov 2014actual | — | 2016-10-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Bladder Cancer is matched — 13 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Bladder Cancer
- Urinary Bladder Neoplasms
- Non-muscle Invasive Bladder Cancer
- Non Muscle Invasive Bladder Cancer
- NMIBC
- Bladder Neoplasms
- Muscle Invasive Bladder Cancer
- Non-muscle-invasive Bladder Cancer
- Superficial Bladder Cancer
- Urinary Bladder Neoplasm
- Metastatic Bladder Cancer
- Muscle-Invasive Bladder Cancer
- Non-Muscle Invasive Bladder Carcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Bladder Cancer” (a text search, wider than this page)